Sirolimus News and Research

RSS

New stent appears safe and effective for preventing arteries from reclosing in coronary heart disease patients

A new stent appears safe and effective for preventing arteries from reclosing in coronary heart disease patients, based on one-year results of the first human trial using this stent reported in today’s rapid access issue of Circulation: Journal of the American Heart Association.

6 May 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004

Patients with coronary artery blockages can be treated safely using drug coated stents

The researchers followed 155 consecutive patients treated with multiple sirolimus-eluting stents between April 2002 and March 2003. Each patient had at least two lesions blocking blood flow in different coronary arteries. Earlier studies have demonstrated that patients with a single, simple artery narrowing held open with a sirolimus-eluting stent are less likely to need retreatment than similar patients who received a bare metal stent. However, those studies excluded patients with complex or multiple artery lesions.

6 Apr 2004

Cordis Cardiology receives warning from the U.S. Food and Drug Administration

Cordis Cardiology, a division of Cordis Corporation, a Johnson & Johnson Company, reported today that it received a warning letter from the U.S. Food and Drug Administration (FDA) regarding FDA's observations concerning the Good Manufacturing Practice (GMP) regulations.

5 Apr 2004